#United States #Mountain View #Cellecta #DriverMap #Immune Profiling

Cellecta, Inc. Expands Its Immune Profiling Portfolio with DriverMap™ Single-Cell AIR Kits

In a significant advance for immune research, Cellecta, Inc., renowned for its innovations in functional genomics and immune profiling technologies, has unveiled its new DriverMap™ Single-Cell Adaptive Immune Receptor (scAIR) kit line. These pioneering kits are designed specifically to provide researchers with cost-effective and high-resolution pairing data of full-length T-cell and B-cell receptors without the usual requirement for intricate instruments or expensive reagents.

Overview of the DriverMap™ scAIR Product Line

The DriverMap scAIR collection comprises eight distinct kits. Each kit facilitates the detailed profiling of T-cell receptor (TCR) and B-cell receptor (BCR) chain pairing for human, mouse, or hybrid samples. Among these options, two specialized kits tailored for human samples also deliver comprehensive immunophenotyping data based on well-known T-cell and B-cell markers.

This innovative suite of assays enables the full-length characterization of TCR α/β and BCR heavy/light chain sequences, serving multiple applications vital in today's biomedical landscape, such as biomarker identification, epitope mapping, immunotherapy advances, and neo-antigen discovery.

Simplifying Complex Workflows

One of the standout features of these scAIR assays is their straightforward multiplex PCR-based protocol. Researchers can utilize indexed primers to effectively identify TCR α/β and BCR heavy/light chain pairs from single transferred cells or to decipher gene sequences from broader populations. Earlier barriers due to complex workflows and the necessity for specialized machinery are now swept away, empowering a larger demographic of scientists to delve into the deep intricacies of immune clonality and functionality at the single-cell level.

Dr. Alex Chenchik, President and Chief Scientific Officer at Cellecta, emphasized the importance of this advancement by stating, "By eliminating the need for specialized hardware and significantly reducing costs per sample, these scAIR kits democratize access for a wider range of researchers to explore immune functionality and cell behavior at unprecedented resolution."

Integration with Current Technologies

Optimized for seamless functionality with Illumina's next-generation sequencing (NGS) platforms, the DriverMap scAIR kits easily fit into standard laboratory protocols. By producing NGS-ready libraries imbued with proprietary validator barcodes from Cellecta, the methodologies remain reliable without relying on the complexities of droplet microfluidics or other partition-based systems.

Given the landscape of high-throughput TCR- or BCR-sequencing systems which typically saddle users with hefty upfront hardware costs, the DriverMap scAIR Kits emerge as a practical and accessible option. They are particularly advantageous for researchers interested in delineating known cell populations or searching for novel insights from less prevalent cell subsets.

Applications of DriverMap™ scAIR Kits

Some of the core applications where these kits excel include:

• - Examination of rare or limited immune samples
• - Profiling of sorted or antigen-specific T and B cell populations
• - Advancing research frontiers in immune monitoring, antibody formulation, and TCR-centric therapies

Once data is collected, analyzing it can be performed using the familiar MiXCR analysis pipeline and Platforma user interface provided by MiLaboratories Inc., integrating functionalities that include V(D)J annotation, clonotype clustering, and chain pairing analysis.

Expansion of DriverMap AIR Offerings

The DriverMap scAIR TCR-BCR assays represent the latest introduction to Cellecta's comprehensive DriverMap AIR portfolio, which already encompasses bulk AIR DNA and RNA kits, spike-in standards, and bioinformatics analytics. Researchers looking for more information can explore the details on Cellecta's official website.

About Cellecta, Inc.

Cellecta, Inc. stands as a trusted contributor to genomic advancement, supplying products and services that bolster drug target and biomarker discovery. Since its inception in 2006, the company has partnered with top-tier pharma, biotech companies, government agencies, and academic institutions globally. Drawing upon its extensive background in immune and transcriptome profiling, cell engineering, and viral vector production, Cellecta delivers innovative solutions driving significant findings across the scientific sphere. For more information, visit www.cellecta.com.